Binds Receptor

Binds Receptor patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/02/07 - 20070178089 - Mucosal vascular addressins and uses thereof
The present invention relates to isolated antibodies and antigen-binding fragments that selectively bind human MAdCAM. ...

08/02/07 - 20070178088 - Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunoglobulin folds, bgs2, 3 and 4 and variants thereof
The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides ...

08/02/07 - 20070178087 - Method for treating immune dysfunction by regulation of cd40 ligand expression
Techniques for treating immune dysfunction in a patient by regulation of CD40 Ligand (CD40L) expression are provided. For example, one technique includes suppressing TFE3 and/or TFEB in the patient to thereby suppress CD40L expression in the patient. In addition, the technique may include administering a TFE3 inhibitor and/or a TFEB ...

08/02/07 - 20070178086 - Monoclonal antibody against abca1
The present invention provides a binding domain of ABCA1, wherein binding of a ligand to the domain is capable of modulating the biological activity of ABCA1. Also provided are methods for screening compounds capable of modulating ABCA1 activity, and antibodies useful in modulating ABCA1 activity. ...

07/26/07 - 20070172476 - Method of treating b-cell neoplasms or hodgkin's lymphoma
The present invention relates to a method for injuring or depleting a B-cell neoplasm cell or a Hodgkin's lymphoma cell and a method for treating B-cell neoplasm or Hodgkin's lymphoma, wherein each method comprises administering to a patient a monoclonal antibody which specifically binds to a human CC chemokine receptor ...

07/26/07 - 20070172475 - Highly concentrated, liquid formulations of anti-egfr antibodies
The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and/or one of its variants and/or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore ...

07/12/07 - 20070160603 - Antibodies against tumor necrosis factor delta (april)
The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, treating, preventing, or ameliorating a disease or disorder associated with aberrant APRIL or APRIL receptor expression or aberrant ...

07/12/07 - 20070160602 - Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth
The present invention provides compositions that enhance or inhibit the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors, and methods for the use thereof as physiological modulators of cell adhesion and in treatment of tumors, both in vivo or ex vivo. It further ...

07/12/07 - 20070160601 - Neutralizing antibodies against primate psgl-1 and uses therefor
This application relates to neutralizing antibodies that specifically bind primate PSGL-1, as well as their production and use. The antibodies reduce one or more activities of PSGL-1, such as human PSGL-1. Methods to detect or quantitate PSGL-1 in a biological sample by adding an antibody that specifically binds to PSGL-1 ...

07/12/07 - 20070160600 - Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications. ...

07/05/07 - 20070154475 - Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies ...

07/05/07 - 20070154474 - Human prostate specific g-protein receptor hpraj70
The present invention relates to PSGR, a novel prostate specific gene with homology to a G-protein coupled receptor overexpressed in prostate cancer. More specifically, the invention relates to PSGR polynucleotides and the polypeptides encoded by these polynucleotides, and the use of PSGR polynucleotides and polypeptides for detecting disorders of the ...

06/28/07 - 20070148169 - Therapeutic agent for chronic arthritides diseases of childhood-related diseases
A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient. ...

06/21/07 - 20070141051 - Nucleic acid encoding cytokine receptor zcytor17
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ...

06/14/07 - 20070134237 - Human cytokine receptor
Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.” ...

06/07/07 - 20070128187 - Reagents and method for modulating dkk-mediated interactions
The present invention provides reagents, compounds, compositions, and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related ...

06/07/07 - 20070128186 - Proliferative glomerulonephritis-related gene
A gene which is useful in searching for a therapeutic agent which restores tissue that suffered damage in a renal disease, a polypeptide encoded by the gene and an antibody which recognizes the polypeptide, are provided. A gene whose expression level changes depending on progression and recovery of the pathology ...

06/07/07 - 20070128185 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, ...

06/07/07 - 20070128184 - Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other ...

05/31/07 - 20070122405 - Human g-protein chemokine receptor (ccr5) hdgnr10
The present invention relates to a human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, ...

05/24/07 - 20070116702 - Survival promoting ncam binding and mcam ligand binding compounds
The present invention relates to compounds capable of stimulating survival of cells presenting the neural cell adhesion molecule (NCAM) or an NCAM-ligand (counter-receptor), such as neurons. Further, the present invention relates to the use of pharmaceutical compositions and medicaments in the treatment or protection of cells presenting NCAM or NCAM ...

05/24/07 - 20070116701 - Compositions and methods for diagnosing and treating cancer
An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth. ...

05/17/07 - 20070110745 - Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders. ...

05/17/07 - 20070110744 - Lymphatic and blood endothelial cell genes
The invention provides polynucleotides and genes that are differentially expressed in lymphatic versus blood vascular endothelial cells. These genes are useful targets for treating diseases involving lymphatic vessels, such as lymphedeman, various inflammatory diseases, and cancer metastasis via the lymphatic system. ...

05/03/07 - 20070098716 - Toll like receptor 3 modulators, methods and uses
Toll Like Receptor 3 (TLR3) modulators, such as antibodies, polynucleotides encoding TLR3 antibodies or fragments thereof, and methods of making and using the foregoing are disclosed. ...

05/03/07 - 20070098715 - Antibodies against the tenascin major antigens
The invention described herein relates to antibodies directed to the antigen Ten-M2 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen Ten-M2. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to ...

05/03/07 - 20070098714 - Preventive agent for vasculitis
To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient. ...

04/26/07 - 20070092514 - Novel secreted immunomodulatory proteins and uses thereof
The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding ...

04/26/07 - 20070092513 - Erbb4 antagonists
The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing ...

04/26/07 - 20070092512 - Preventing bacterial or viral infectivity and composition containing infection preventing additive
A nitric oxide synthesis inhibitor or nitric oxide scavenger is administered to prevent development of infection, to prevent development of a cancer where overstimulation of a receptor contributes to the cancer development, and to prevent loss of beta agonist responsivity and as a treatment in combination with a receptor blocker. ...

04/26/07 - 20070092511 - Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ...

04/26/07 - 20070092510 - Cns chloride modulation and uses thereof
Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and/or expression of a chloride transporter, such ...

04/19/07 - 20070086997 - Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
The present invention concerns thirteen novel variants of alternative splicing of the obesity and/or diabetes related genes. ...

04/12/07 - 20070081992 - Fusion proteins for blood-brain barrier delivery
The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the ...

04/05/07 - 20070077244 - Inhibitor protein of the wnt signal pathway
The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein. ...

03/22/07 - 20070065432 - Antibody fragment-targeted immunoliposomes for systemic gene delivery
A targeted vector allowing enhanced gene transfer to human hepato-cellular carcinoma (HCC1) cells in vitro was developed using cationic liposomes covalently conjugated with the mAb AF-20. This high affinity antibody recognizes a rapidly internalized 180 kDa cell surface glycoprotein which is abundantly expressed on the surface of human HCC and ...

03/22/07 - 20070065431 - V-like domain binding molecules
The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the ...

03/22/07 - 20070065430 - Nogo-a neutralising immunoglobulins for treatment of neurological diseases
The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases. ...

03/22/07 - 20070065429 - Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
The invention provides methods for treating diseases involving aberrant amyloid-β (Aβ) peptide deposition, including Alzheimer's Disease, by the administration of Nogo receptor antagonists. The invention also provides method for reducing levels of Aβ peptide in a mammal by the administration of soluble Nogo receptor polypeptides ...

03/15/07 - 20070059305 - Neutralizing human anti-igfr antibody
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention. ...

03/15/07 - 20070059304 - Anti-trkb monoclonal antibodies and uses thereof
The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal ...

03/08/07 - 20070053902 - Anti-alphabeta3 humanized monoclonal antibodies
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin αvβ3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of αvβ3-mediated disorders, such as restenosis, in human patients. ...

03/01/07 - 20070048304 - Method of treating allergy using antibody against human interleukin-5 receptor alpha chain
The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor α chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor α chain immunologically by means of these ...

03/01/07 - 20070048303 - Nucleic acid encoding cytokine receptor zcytor17
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ...

03/01/07 - 20070048302 - Peptides of il-2
The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents. ...

03/01/07 - 20070048301 - Compositions and methods for the treatment of immune related diseases
The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. ...

02/22/07 - 20070041970 - Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the ...

02/22/07 - 20070041969 - Apo-2dcr
Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided. ...

02/15/07 - 20070036785 - Pharmaceutical composition for treatment of diseases caused by il-6 production
Pharmaceutical compositions for prevention or treatment of diseases caused by interleukin-6 production, comprising an antibody to interleukin-6 receptor (IL-6R antibody). As the IL-6R antibody, an antibody of animals other than the human such as mice, rats, etc., a chimeric antibody between these and a human antibody, a reshaped human antibody, ...

02/15/07 - 20070036784 - Medicament for the protection against thrombotic diseases
A medicament for the protection against thrombotic diseases is described that comprises an active principle which induces irreversible inactivation or degradation of the collagen receptor on thrombocytes. Antibodies, especially the humanized monoclonal antibody JAQ1, are the preferred active principle. Further a diagnostic agent for the determination of the expression rate ...

02/15/07 - 20070036783 - Antibody complexes
This invention is directed to a soluble complex of ligands that binds to surface molecules of hemopoietic cells and result in their activation or expansion. The complex may be used in the activation and/or expansion of hemopoietic cells, optionally in combination with their transduction. The complex of ligands bind at ...

02/15/07 - 20070036782 - Apo-2 ligand
A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand ...

02/15/07 - 20070036781 - Ligands
A method of detecting an agent that modulates the activity of CCRL2, the method comprising: (a) contacting a CCRL2 polypeptide with a macrophage inflammatory protein-4 (MIP-4) polypeptide in the presence of a candidate agent under conditions, which in the absence of the test agent, permit the binding of the MIP-4 ...

02/01/07 - 20070025986 - Modulation of hcn channels by second messengers
The present invention relates to modulation of the activation of hyperpolarization-activated cyclic-nucleotide-sensitive cation non-selective (HCN) channels by second messengers. The present invention provides methods for modulating the activation of HCN channels, methods for the treatment and prevention of disorders associated with abnormality in HCN channel functions, and methods of screening ...

01/25/07 - 20070020262 - Uses of mammalian cytokine: related reagents
Provided are methods of modulating dendritic cell activity using agonists or antagonists of a mammalian cytokine. Also provided are methods of treating immune disorders. ...

01/18/07 - 20070014794 - Method for making heteromultimeric polypeptides
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the ...

01/18/07 - 20070014793 - Antibodies which activate an erythropoietin receptor
Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia. ...

01/18/07 - 20070014792 - Egfr inhibitors promote axon regeneration
Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron. ...

01/18/07 - 20070014791 - Rage-related methods and copositions for treating glomerular injury
This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating glomerular injury. The instant invention is based on the blockade of RAGE and/or RAGE G82S function. ...

01/18/07 - 20070014790 - Transcription control factor zhx3
To determine the biological role of ZHX1, found previously, which acts as a transcriptional repressor, the inventors conducted a search of ZHX1—interacting proteins using a yeast two-hybrid system. Molecular cloning and determination of the nucleotide sequence of the full-length cDNA encoding a novel protein revealed a novel protein with SEQ ...

01/11/07 - 20070009514 - Prostaglandin receptor ep1
The polypeptide of the present invention can be used for treating diseases, which is caused by over production of PGE2, such as pain, fever and pollakiuria. ...

01/11/07 - 20070009513 - Novel method of screening
The use of a G-protein coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof and a ligand peptide comprising the amino acid sequence represented by any of SEQ ID NO: 3 ...

12/21/06 - 20060286103 - Stable antibody formulation
The present invention provides a pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof that exhibits high stability; along with methods of use thereof. ...

12/21/06 - 20060286102 - Cell surface receptor isoforms and methods of identifying and using the same
Isoforms of cell surface receptors, including isoforms of receptor tyrosine kinases, and pharmaceutical compositions containing the isoforms are provided. Chimeras of and conjugates containing the cell surface receptors that contain a portion, such as an extracellular domain, from one cell surface receptor, and a second portion, particularly an intron-encoded portion, ...

12/14/06 - 20060280739 - Novel human beta-2 integrin alpha subunit
Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNFα release from cells expressing αd are disclosed. ...

12/07/06 - 20060275288 - Glp-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
The subject invention relates to monoclonal antibodies that have the ability to bolster the function of the GLP-1 receptor and may therefore have utility in the treatment of mammalian metabolic disorders such as, for example, diabetes. In particular, the invention describes the generation of fully human monoclonal antibodies made against ...

12/07/06 - 20060275287 - Scroll compressor
A scroll compressor that is easy of back pressure adjustment and capable of realizing high compression efficiency. The scroll compressor comprises a plurality of compression spaces formed by fixed spiral blades meshing with rotary spiral blades, a back pressure chamber disposed on the side opposite to the rotary spiral blade ...

11/30/06 - 20060269547 - Humanized anti-cd3 specific antibodies
Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression. ...

11/30/06 - 20060269546 - Androgen-regulated pmepa1 gene and polypeptides
This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer. ...

11/30/06 - 20060269545 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such ...

11/16/06 - 20060257400 - Combination therapy
This invention relates to a therapeutic combination of anti-cancer compounds which comprises a) a VEGFR-2 inhibitor, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to initiate receptor activities which results in tumor growth inhibition, and optionally ...

11/16/06 - 20060257399 - Immunoglobulins comprising predominantly a man5gicnac2 glycoform
The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2. ...

11/09/06 - 20060251650 - Antagonists of neuroplin receptor function and use thereof
The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases. ...

11/09/06 - 20060251649 - Treatment of non-convulsive seizures in brain injury using g-2-methyl-prolyl glutamate
Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury. ...

11/09/06 - 20060251648 - Transient receptor potential channel trpv3 and its use
This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain. ...

11/09/06 - 20060251647 - Apo-2 receptor
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. ...

11/09/06 - 20060251646 - Anti-tirc7 antibodies in therapy of inflammatiory diseases
A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises particular therapeutic and preventive treatment regimens for the administration of a T-cell immune response cDNA 7 (TIRC7) antagonist, preferably an anti-TIRC7 antibody. Particularly useful monoclonal, in particular chimeric anti-TIRC7 antibodies are described. ...

11/02/06 - 20060246065 - Fail molecules and uses thereof
The invention provides isolated nucleic acid molecules, designated FAIL, which encode polypeptide molecules containing Ig and Ig-like domains and which are homologous to FcγRI. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have ...

11/02/06 - 20060246064 - Osteoprotegerin binding proteins
A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. ...

11/02/06 - 20060246063 - Method for detecting regulatory t cells using expression of folate receptor 4 as indicator, method for treating diseases using the detection method, pharmaceutical composition for immunostimulation, and method for treating diseases using the composition
In the method of the present invention, Treg cells are detected from test cells containing (i) regulatory T cells and (ii) at least one type of cell selected from the group consisting of naive T cells and activated T cells, wherein expressions of folate receptor 4 on the surfaces of ...

11/02/06 - 20060246062 - Anti-ccr4 antibodies and methods of use therefor
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a ...

10/26/06 - 20060240004 - Methods for treating tweak-related conditions
The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that ...

10/19/06 - 20060233792 - Train-r: a cysteine rich member of the tnf-receptor family
Novel receptor in the TNF family: TRAIN-receptor. ...

10/12/06 - 20060228354 - Modified adamts4 molecules and method of use thereof
The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also ...

10/12/06 - 20060228353 - Pth1r and pth3r receptors, methods and uses thereof
The present invention relates to novel parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) receptors (PTH1R and PTH3R) isolated from zebrafish. The receptors of the present invention share homology with previously identified parathyroid hormone (PTH)/parathyroid related protein (PTHrP) receptors. Isolated nucleic acid molecules are provided encoding the zebrafish PTH1R ...

09/28/06 - 20060216289 - Gfralpha3 and its uses
The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFRα3, a novel α-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an α-subunit ...

09/28/06 - 20060216288 - Combinations for the treatment of cancer
This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer. ...

09/28/06 - 20060216287 - Eph-like receptor protein tyrosine kinases
Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed. ...

09/28/06 - 20060216286 - Novel screening method
By using a G protein-coupled receptor protein comprising an amino acid sequence, which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and an ionizable metal element or a salt thereof, an agonist for or an antagonist ...

09/21/06 - 20060210561 - Dosages for treatment with anti-egfr antibodies
The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody. ...

09/21/06 - 20060210560 - Tnf receptor action modulaton
A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the normal functioning of the TNF-Rs. Such peptides or other molecules may be ...

09/21/06 - 20060210559 - Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving ...

09/14/06 - 20060204496 - Agonist antibody against heteroreceptor
Animals were immunized with either the A or B chain of a receptor, and then mRNA was extracted from the spleen cells of the animals, and the variable regions of the L and H chains were isolated by RT-PCR using primers for variable regions comprising CDRs. Single-chain Fv was synthesized ...

09/07/06 - 20060198842 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction ...

09/07/06 - 20060198841 - Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
The present invention provides Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells, and methods for its production. The invention also provides methods for the identification of homologues in other species and of DmGPCR agonists/antagonists useful ...

08/31/06 - 20060193854 - Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ...

08/31/06 - 20060193853 - Combinations of growth-and hormone-regulating factors for the treatment of neoplasia
The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or ...

08/24/06 - 20060188501 - Diagnostic and therapeutic agents for rheumatoid arthritis
The present invention provides a therapeutic agent for rheumatoid arthritis which inhibits the growth of synoviocytes mediated by c-erbB-2 by clarifying the participation of c-erbB-2 in the growth of synoviocytes in rheumatoid arthritis patients and inhibiting the activation or expression of c-erbB-2. ...

08/24/06 - 20060188500 - Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population. ...

08/24/06 - 20060188499 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne ...

08/24/06 - 20060188498 - Methods of using death receptor agonists and egfr inhibitors
Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with ...

08/17/06 - 20060182743 - Methods of treating skin disorders using an il-31ra antagonist
The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist. ...

08/10/06 - 20060177441 - Agonist antibodies
Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia. ...

08/10/06 - 20060177440 - Compositions and methods for detection of antibody binding to cells
The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included. ...

08/10/06 - 20060177439 - Fcgammariib-specific antibodies and methods of use thereof
The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention ...

08/10/06 - 20060177438 - Methods of altering absorption of hydrophobic compounds
This invention presents methods of increasing intestinal motility rates in order to decrease intestinal absorption of cholesterol. Furthermore, this invention presents methods of modulating intestinal motility in order to influence positively the amount of drug or nutrient absorption from the intestine, especially of hydrophobic drugs or nutrients. The instant methods ...

08/03/06 - 20060171944 - N-formyl peptide receptor mediation of platelet chemotaxis toward injured cells and activation of immune response
The present invention relates to N-formyl peptides that induce an immune response, specifically, stimulating mobilization of platelets to a site of injury, thereby healing wounds. Further, the invention relates to N-formyl peptide receptor inhibitors, specifically N-formyl peptide receptor antibodies, that inhibit an immune response, thereby blocking inflammation and the mobilization ...

07/27/06 - 20060165687 - Vaccine adjuvant
The present invention relates, in general, to a method of enhancing an immune response in a mammal and, in particular, to a method of enhancing an immune response to a vaccine comprising suppressing the number and/or function of regulatory T cells. The invention further relates to compounds and compositions suitable ...

07/27/06 - 20060165686 - Combining therapies targeting multiple toll-like receptors and use thereof
The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions in the treatment of inflammatory disorders. ...

07/27/06 - 20060165685 - Bispecific anti-erb-b antibodies and their use in tumor therapy
The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding ...

07/27/06 - 20060165684 - Therapeutic anti-tirc7 antibodies for use in immune related and other diseases
Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided. ...

07/27/06 - 20060165683 - Methods and compositions for control of bone formation via modulation of sympathetic tone
This invention relates to methods for treatment, diagnosis and prevention of bone disease and comprises methods including measurement and modulation of sympathetic tone and leptin activity. Alteration of sympathetic tone in bone disease can be accomplished by decreasing or increasing leptin synthesis, leptin receptor synthesis, leptin binding to the leptin ...

07/20/06 - 20060159681 - Compositions and methods to inhibit cell loss by using inhibitors of bag
The present invention relates to inhibitors of BAG and uses thereof, such as to inhibit cell loss, inhibit parkin sequestration, and/or inhibit formation of protein aggregates. More specifically, the present invention relates to BAG inhibitors used to inhibit neurodegeneration and to treat a neurodegenerative disease, such as Parkinson's disease. ...

07/13/06 - 20060153842 - Immunosuppressive combination and its use in the treatment or prophylaxis or insulin-producing cell graft rejection
A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or ...

07/13/06 - 20060153841 - B7-4 polypeptides and uses therefor
The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a ...

07/13/06 - 20060153840 - Methods for preventing or treating a condition or a disease associated with angiogenesis
A method for regulating angiogenesis in a subject in need thereof, comprising administering to said subject an effective amount of a substance capable of modulating the activity of a netrin-1 receptor. ...

07/13/06 - 20060153839 - Production of bispecific molecules using polyethylene glycol linkers
The invention relates to a bispecific molecule comprising a first recognition binding moeity that binds a Cab-like receptor cross-linked using a poly-(ethylene glycol) (“PEG”) linker with one or more second recognition binding moieties that bind a molecule. The invention also relates to methods of producing such bispecific molecules and to ...

07/06/06 - 20060147449 - Method of using cd100 (or sema4d) to mediate platelet activation and inflammatory responses
This invention relates to methods of treating platelet disorders and/or endothelial cell disorders by modulating sema4D/CD100 activity. Specifically, this invention involves the use of compounds to increase or decrease the level of soluble sema4D/CD100. ...

07/06/06 - 20060147448 - Treatment of immunological renal disorders by lymphotoxin pathway inhibitors
The disclosure relates to treatment of immunological disorders, including but not limited to renal disorders associated with immunoglobulin deposits. The disclosure further relates to the lymphotoxin pathway. Compositions comprising lymphotoxin pathway inhibitors are described. ...

07/06/06 - 20060147447 - Secreted peptides
The invention provides secreted active peptides, methods and compositions for making such peptides, and methods of using the peptides in detection assays, for disease diagnosis, for disease treatment and for drug development. ...

06/29/06 - 20060140942 - Human g-protein coupled receptor (hetgq23)
Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat ...

06/29/06 - 20060140941 - Growth differentiation factor-3
Growth Differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3 polypeptide and polynucleotide sequences. ...

06/29/06 - 20060140940 - Anti-hgf-r antibodies and their use
The present invention relates to monoclonal antibodies which recognize the chain of the HFG receptor with the agonist activity of the natural ligand. The invention also relates to the hybridoma which secretes said antibodies and to their therapeutic and diagnostic use. ...

06/29/06 - 20060140939 - Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
A method for preventing or treating tissue damage associated with ischemia-reperfusion injury and thoraco-abdominal aortic aneurysm (TAAA) repair by administering a tissue damage preventing or treating amount of a complement inhibitor to a patient likely to suffer from or suffering from tissue damage associated with ischemia-reperfusion injury or TAAA repair. ...

06/29/06 - 20060140938 - Monoclonal antibody specific for ppar gamma, hybridoma cell line producing the same, and method for detecting regulator related to diseases, including inflammation, cancer and metabolic diseases, using the same
The present invention relates to a hybridoma cell line producing a PPAR gamma-specific monoclonal antibody, and a method for detecting a PPAR gamma ligand related to the progression of difficult diseases, such as cancer, inflammation and metabolic diseases obesity and diabetes), using the PPAR gamma-specific monoclonal antibody. This PPAR gamma-specific ...

06/22/06 - 20060134109 - G protein coupled receptors and uses thereof
The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) ...

06/15/06 - 20060127397 - Rag polypeptides, nucleic acids, and their use
The present invention relates generally to regeneration associated genes (RAGs). More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of RAGs and RAG polypeptides. The invention further relates to methods of detecting, preventing, and treating RAG-associated disorders. ...

06/15/06 - 20060127396 - Peptide fragment of lyve-1 and antibody against the same
It is intended to provide a specific peptide fragment of LYVE-1 which can serve as an epitope of a lymphatic vessel-specific antibody, and an antibody recognizing the above peptide fragment. A peptide fragment comprising an amino acid sequence: Ser Lys Lys Thr Asp Lys Asn Pro Glu Glu Ser Lys, ...

06/01/06 - 20060115475 - Toll like receptor 3 antagonists, methods and uses
Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. ...

05/25/06 - 20060110386 - Mammalian cytokines; receptors; related reagents and methods
Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. ...

05/25/06 - 20060110385 - Means and methods for diagnosing and treating affective disorders
The present invention relates to nucleic acid molecules, preferably genomic sequences, encoding an ATP-gated ion channel P2X7R which contain a mutation in the 5′UTR or 3′UTR regions, a mutation in exon 3, 5, 6, 8 or 13 or in introns 1, 3, 4, 5, 6, 7, 9, 11 or 12 ...

05/25/06 - 20060110384 - Novel proteins and use thereof
The present invention provides a novel secretory/membrane protein associated with adipocyte differentiation and/or metabolism function, specifically, an adipocyte-derived secretory/membrane protein containing amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, ...

05/18/06 - 20060104973 - Reducing ngr-p75 mediated inhibition of axon regeneration
Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration. ...

05/18/06 - 20060104972 - Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 ...

05/18/06 - 20060104971 - Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
Multivalent antibody constructs that are specific for the human lymphotoxin beta receptor, as well as their use in treating cancer and inhibiting tumor volume in a subject are disclosed. ...

05/11/06 - 20060099210 - Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia ...

05/04/06 - 20060093603 - Erbb4 antagonists
The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing ...

04/27/06 - 20060088530 - Photodynamic therapy treatment for eye disease
This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a ...

04/27/06 - 20060088529 - Bispecific monoclonal antibodies to il-12 and il-18
A bispecific monoclonal antibody is described which comprises two moieties, one of which comprises an antigen-binding region which is specific for either the IL-12Rβ1 or the IL-12Rβ2 subunit of an IL-12 receptor, and the other of which comprises an antigen-binding region which is specific for either the IL-18R or the ...

04/27/06 - 20060088528 - Methods and compositions for treating alzheimer's disease
The present invention relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or ...

04/20/06 - 20060083738 - Treatment of cancer by the use of anti fas antibody
The present invention provides a method of killing cancer cells and method of treatment of cancer comprising administration of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent. The ...

04/13/06 - 20060078559 - Ligand for g-protein coupled receptor fprl2 and uses thereof
The present invention relates to methods, reagents and kits for detecting of formyl peptide receptor like-2 (FPRL2) polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against FPRL2. It further relates to substances for preventing, treating and/or alleviating diseases or disorders ...

04/13/06 - 20060078558 - Diagnosis, prognosis and treatment of pulmonary diseases
The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. Methods are provided for supplying FoxA2 function to cells ...

03/30/06 - 20060067934 - Glycoproteins which bind to tnf
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed. ...

03/30/06 - 20060067933 - Soluble receptor br43x2 and methods of using
Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and ...

03/23/06 - 20060062786 - Antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptors. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TRAIL receptor antibodies, vectors and host cells containing these ...

03/23/06 - 20060062785 - Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia). ...

03/16/06 - 20060057144 - Fc receptor modulators and uses thereof
This invention relates to a method of inhibiting FC receptor binding of immunoglobulin comprising the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating ...

03/16/06 - 20060057143 - Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (ccr11)
The invention provides a human CCR11 which is associated with the disorders of the peripheral and central nervous system, cardio-vascular diseases, genitourinary diseases, metabolic diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and ...

02/23/06 - 20060039908 - Transferrin receptor antibodies
The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor. ...

02/23/06 - 20060039907 - Method and compositions for treating diseases targeting cd71
Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD71 in comparison to healthy cells. Also provided are antagonists or agonists of CD71, and methods for screening agents that modulate the CD71 level or activity in vivo or in vitro. ...

02/16/06 - 20060034843 - Interaction of smad6 with hox proteins and uses thereof
The present invention describes a novel interaction between Smad6 and the Hox genes in nuclear transcriptional regulation following BMP signal transduction. The present invention further provides methods of using this novel Smad6/Hox protein interaction to regulate gene expression, regulate bone formation and control osteoporosis. Further provided are methods of screening ...

02/16/06 - 20060034842 - Treatment with anti-erbb2 antibody combinations
The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations. ...

02/16/06 - 20060034841 - Method of depleting regulatory t cell
The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering ...

02/16/06 - 20060034840 - Erbb antagonists for pain therapy
The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain. ...

02/16/06 - 20060034839 - Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the ...

02/09/06 - 20060029605 - Use of erbb receptor ligands in treating diabetes
The invention provides methods for treating pancreatic dysfunction, particularly diabetes, in mammals using ErbB receptor ligands, such as heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such therapeutically useful ...

02/09/06 - 20060029604 - Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GlcNAc2Man3GlcNAc2. ...

02/09/06 - 20060029603 - Immunoglobulins
The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ...

02/09/06 - 20060029602 - Gamma-heregulin
A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. γ-HRG polypeptide and nucleic acid are ...

02/09/06 - 20060029601 - Interferon alpha receptor 1 antibodies and their uses
The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated ...

02/02/06 - 20060024304 - Immunoglobulins comprising predominantly a man5glcnac2 glycoform
The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2. ...

01/26/06 - 20060018902 - Antibodies to erythropoietin receptor and uses thereof
The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a ...

01/19/06 - 20060013814 - Methods for preventing pressure-induced apoptotic neural-cell death
Compositions and methods for protecting neuronal cells from pressure-induced apoptotic cell death which comprises administering to a subject in need of such treatment at least one compound which directly or indirectly inhibits the activity of an ion channel on neuronal cells and thereby inhibits the effect of pressure on the ...

01/05/06 - 20060002926 - C-c chemokine receptor 3 proteins
The present invention relates to isolated and/or recombinant C—C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides. ...

01/05/06 - 20060002925 - Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes ...

01/05/06 - 20060002924 - Conjugate of notch signalling pathway modulators and their use in medical treatment
Conjugates comprising a plurality of modulators of the Notch signalling pathway chemically bound to a support structure are described. The conjugates are useful for modulation of the Notch signalling pathway and treatment of associated conditions. ...

01/05/06 - 20060002923 - Recombinant anti-osteopontin antibody and use thereof
A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the ...

12/29/05 - 20050287139 - Wound healing
A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralizing agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of the composition ...

12/29/05 - 20050287138 - Ccr4-specific antibody composition
The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine ...

12/22/05 - 20050281814 - Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody
This invention comprises a method of inhibiting tumor growth in tumors having growth factor receptors comprising administering, about simultaneously, antibodies to the target growth factor receptors, at least one chemotherapeutic agent and radiation therapy. ...

12/22/05 - 20050281813 - Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or ...

12/22/05 - 20050281812 - Antibodies to insulin-like growth factor i receptor
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to ...

12/15/05 - 20050276804 - Method for preventing or treating cardiac hypertrophy
A method for treating or preventing cardiac hypertrophy in a mammal, comprising manipulating levels of RBP, retinoids, or an affiliated signaling and regulatory pathway in the mammal. Preferably, the method comprises reducing or inhibiting the level of RBP or retinoids or their signaling pathway, or an affiliated signaling pathway, via ...

12/08/05 - 20050271656 - Methods for designing specific ion channel blockers
The present invention relates to a method of designing an ion channel blocker for an ion channel which includes providing an ion channel having an external vestibule portion and raising an antibody, binding portion, probe, or ligand specific to the external vestibule portion of the ion channel, where the antibody, ...

12/08/05 - 20050271655 - Nogo receptor antagonists
Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof ...

12/01/05 - 20050266000 - Variable domain library and uses
The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may ...

12/01/05 - 20050265999 - Modulation of 5-ht2 receptors as a treatment for cardiovascular diseases
The present invention provides for methods of treating and preventing muscle atrophy, cardiac hypertrophy, heart failure and/or primary pulmonary hypertension linked to a family of serotonin receptors called 5-HT2 receptors. The present invention further demonstrates that modulators of 5-HT2 receptors can inhibit or treat muscle atrophy, heart failure, cardiac hypertrophy, ...

12/01/05 - 20050265998 - Neutralizing antibodies and methods of use thereof
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods ...

11/24/05 - 20050260197 - Receptor for oncostatin m
A novel polypeptide functions as the β chain of an oncostatin M receptor and is thus designated OSM-Rβ. Heterodimeric receptor proteins comprising OSM-Rβ and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M. ...

11/17/05 - 20050255105 - Severe myelin deficits induced by self-reactive gamma delta t cells
Recognition of ligands on myelinated axons by specific γδ T cells can induce demyelination. Among the ligands of interest are MHC molecules, including non-classical class I MHC molecules, which are shown to be expressed in cells of the oligodendrocyte lineage. These events provide a basis for initiating events of inflammatory ...

11/17/05 - 20050255104 - Methods of treating psoriasis using anti-tnf receptor fusion proteins
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of ...

11/17/05 - 20050255103 - Remedy for lung cancer
The present invention provides a pharmaceutical composition for treating lung carcinoma and a diagnostic agent for lung carcinoma. More specifically, the present invention provides a pharmaceutical composition for treating lung carcinoma and a diagnostic agent for lung carcinoma, which comprise an antibody capable of binding to the β-chain of an ...

11/17/05 - 20050255102 - Anti-alphavbeta6 antibodies
Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases. ...

11/17/05 - 20050255101 - Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen and optionally further comprises an identifiable or therapeutic moiety conjugated to the antibody. ...

11/10/05 - 20050249730 - Novel anti-igf-ir and/or anti-insulin/igf-i hybrid receptors antibodies and uses thereof
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as ...

11/10/05 - 20050249729 - Anti-trail-r antibody
Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and (c) not inducing ...

11/03/05 - 20050244409 - Erythropoietin receptor antibodies
Erythropoietin receptor agonist and antagonist antibodies and their use in enhancing erythropoiesis are disclosed. ...

11/03/05 - 20050244408 - Antibodies to insulin-like growth factor i receptor
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to ...

11/03/05 - 20050244407 - Therapeutic synergy of anti-cancer compounds
This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally ...

11/03/05 - 20050244406 - Monoclonal antibodies against extracellular loops of c5ar
The Present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a ...

10/27/05 - 20050238644 - Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-ll-6 receptor antibody as an active ingredient
A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient. ...

10/27/05 - 20050238643 - Modulation of lir function to treat rheumatoid arthritis
This invention relates to methods for treating rheumatoid arthritis (RA) by administering one or more agents that specifically target LIR-2, LIR-3 and LIR-7. Results disclosed herein indicate that these three LIRs may participate in regulating the activation of leukocytes that infiltrate synovial tissue. Thus, inflammation in the joints of RA ...

10/20/05 - 20050232920 - Inhibition of complement activation
The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including ...

10/20/05 - 20050232919 - Monoclonal antibodies that specifically block biological activity of a tumor antigen
This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”), ...

10/20/05 - 20050232918 - Differentially expressed genes associated with obesity and type 2 diabetes
The present invention relates generally to a nucleic acid molecule which is expressed in at least the stomach, hypothalamus or liver identified using differential display techniques under differing physiological conditions. It is proposed that the nucleic acid molecules encode expression products associated with the modulation of obesity, anorexia, weight maintenance, ...

10/13/05 - 20050226871 - Compositions and methods for promoting nerve regeneration
FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or ...

10/13/05 - 20050226870 - Methods for the treatment of inflammatory joint disease
The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are ...

10/13/05 - 20050226869 - Compositions and methods for the treatment of tumor of hematopoietic origin
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. ...

10/13/05 - 20050226868 - Method for treating tumors using anti-osteopontin antibodies
The present invention is directed to compositions of matter useful for the treatment of tumor in mammals and to methods of using those compositions of matter for the same. ...

10/13/05 - 20050226867 - Il-5r-specific antibody composition
The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in ...

10/06/05 - 20050220787 - Naturally occuring igm antibodies that bind to lymphocytes
In this invention, the inventor discloses that naturally occurring IgM anti-lymphocyte antibodies bind to chemokine and non-chemokine receptors on lymphocytes and other cells, and downmodulate certain receptors including CD4 and CD2 on T cells and CD80 and CD86 on macrophages. The inventor also discloses that such antibodies (i) inhibit HIV-1 ...

09/29/05 - 20050214281 - G-protein coupled receptor
A human G-protein coupled receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Also disclosed are diagnostic methods for detecting a mutation in ...

09/22/05 - 20050208047 - Pain signaling molecules
A novel G protein-coupled receptor called MrgC11 has been identified that is expressed in dorsal root ganglia and that is activated by RF amide related peptides. ...

09/22/05 - 20050208046 - Tweak receptor
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac ...

09/22/05 - 20050208045 - Cripto antagonism of activin and tgf-b signaling
Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b.type II.type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative ...

09/22/05 - 20050208044 -